4DMedical’s Cash Swells to $22.9M with R&D Credit and Pro Medicus Investment
4DMedical has bolstered its financial footing with a $6 million R&D tax incentive and a $10 million strategic investment, while its XV LVAS® technology gains clinical validation for predicting serious COPD treatment complications.
- Received $6 million R&D Tax Incentive boosting cash reserves
- Pro Medicus strategic investment lifts proforma cash to $22.9 million
- Potential $22.7 million from exercise of 41 million options by October
- XV LVAS® technology published in leading respiratory journal
- Study shows high accuracy in predicting pneumothorax risk in COPD patients
Financial Strengthening Amid Commercial Rollout
4DMedical Limited (ASX – 4DX), a pioneer in respiratory imaging technology, has announced a significant boost to its financial position with the receipt of $6 million in Research and Development (R&D) Tax Incentive credits. This comes on the heels of a recent $10 million strategic investment from Pro Medicus, bringing the company's proforma cash balance to a robust $22.9 million as of June 30, 2025.
Adding to this financial momentum, approximately 41 million options exercisable at $0.55 each are set to expire on October 1, 2025. If fully exercised, these options could inject an additional $22.7 million into 4DMedical’s coffers, providing ample runway to accelerate the commercial rollout of its CT – VQ™ solution and expand its existing product suite.
Clinical Validation of XV LVAS® Technology
In a parallel development, 4DMedical has achieved a notable clinical milestone with the publication of a study in the American Journal of Respiratory and Critical Care Medicine, one of the most respected journals in respiratory medicine. The study, conducted in collaboration with Temple University Hospital, highlights the unique capabilities of 4DMedical’s XV LVAS® technology in predicting pneumothorax, a potentially life-threatening complication, in patients undergoing bronchoscopic lung volume reduction (BLVR) for advanced Chronic Obstructive Pulmonary Disease (COPD).
BLVR with endobronchial valves offers significant relief for severe COPD patients but carries a 26-34% risk of pneumothorax. The study demonstrated that combining XV LVAS® measurements with standard CT imaging yields a high predictive accuracy (AUC = 0.833, p<0.001) for this complication, enabling clinicians to better stratify patient risk and tailor treatment plans accordingly.
Implications for Patient Care and Market Position
These findings underscore the potential of 4DMedical’s technology to transform respiratory care by providing actionable insights that conventional imaging cannot. By identifying patients at highest risk before intervention, the technology promises to improve patient outcomes and reduce the burden of complications on healthcare systems.
CEO Andreas Fouras emphasized the strategic importance of the strengthened financial position, stating that it equips the company to advance its mission of delivering world-class diagnostic tools globally. COPD remains a critical focus area, being the fourth leading cause of death worldwide, and 4DMedical’s innovations could play a pivotal role in improving management of this challenging disease.
With a solid capital base and growing clinical validation, 4DMedical is well positioned to capitalize on the commercial opportunities ahead, particularly as it scales the deployment of CT – VQ™ and continues to expand its AI-driven respiratory imaging portfolio.
Bottom Line?
4DMedical’s strengthened finances and validated technology set the stage for accelerated growth and deeper clinical impact in respiratory care.
Questions in the middle?
- Will the full tranche of options be exercised before the October expiry, and how will this affect share dilution?
- How quickly will healthcare providers adopt CT, VQ™ technology amid competing respiratory imaging solutions?
- What further clinical evidence or regulatory approvals might 4DMedical pursue to enhance market penetration?
